CR20150466A - Péptidos y composiciones para el tratamiento de daño articular - Google Patents

Péptidos y composiciones para el tratamiento de daño articular

Info

Publication number
CR20150466A
CR20150466A CR20150466A CR20150466A CR20150466A CR 20150466 A CR20150466 A CR 20150466A CR 20150466 A CR20150466 A CR 20150466A CR 20150466 A CR20150466 A CR 20150466A CR 20150466 A CR20150466 A CR 20150466A
Authority
CR
Costa Rica
Prior art keywords
compositions
peptides
treatment
articular damage
damage
Prior art date
Application number
CR20150466A
Other languages
English (en)
Inventor
Kristen Johnson
Jian Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20150466A publication Critical patent/CR20150466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención proporciona nuevos polipéptidos resistentes a la proteasa, así como composiciones y métodos para tratar, mejorar o prevenir condiciones relacionadas con daño articular, incluyendo lesión aguda de articulaciones y artritis.
CR20150466A 2013-03-08 2015-09-08 Péptidos y composiciones para el tratamiento de daño articular CR20150466A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10
PCT/US2014/022102 WO2014138687A1 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Publications (1)

Publication Number Publication Date
CR20150466A true CR20150466A (es) 2015-10-27

Family

ID=50390286

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20200290A CR20200290A (es) 2013-03-08 2014-03-07 PÉPTIDOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DAÑO ARTICULAR (Divisional 2015-0466)
CR20150466A CR20150466A (es) 2013-03-08 2015-09-08 Péptidos y composiciones para el tratamiento de daño articular

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20200290A CR20200290A (es) 2013-03-08 2014-03-07 PÉPTIDOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DAÑO ARTICULAR (Divisional 2015-0466)

Country Status (39)

Country Link
US (4) US9649359B2 (es)
EP (2) EP2964250B1 (es)
JP (3) JP6567429B2 (es)
KR (1) KR102267341B1 (es)
CN (2) CN111808182A (es)
AP (1) AP2015008675A0 (es)
AU (3) AU2014225348B2 (es)
BR (2) BR112015021269B1 (es)
CA (1) CA2903448C (es)
CL (1) CL2015002443A1 (es)
CO (1) CO7461145A2 (es)
CR (2) CR20200290A (es)
CU (1) CU24301B1 (es)
CY (1) CY1120729T1 (es)
DK (1) DK2964250T3 (es)
EA (1) EA035158B1 (es)
EC (1) ECSP15042898A (es)
ES (1) ES2684349T3 (es)
HK (1) HK1214754A1 (es)
HR (1) HRP20181269T1 (es)
HU (1) HUE038499T2 (es)
IL (1) IL240727B (es)
JO (1) JO3564B1 (es)
LT (1) LT2964250T (es)
MX (1) MX365157B (es)
MY (1) MY173172A (es)
NZ (1) NZ711037A (es)
PE (1) PE20151528A1 (es)
PH (1) PH12015501983B1 (es)
PL (1) PL2964250T3 (es)
PT (1) PT2964250T (es)
RS (1) RS57446B1 (es)
SG (1) SG11201506490TA (es)
SI (1) SI2964250T1 (es)
TN (1) TN2015000385A1 (es)
TW (1) TWI634124B (es)
UY (1) UY35368A (es)
WO (1) WO2014138687A1 (es)
ZA (1) ZA201505966B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177318A1 (en) 2009-07-14 2012-03-29 Scripps Research Inst Mesenchymal stem cell differentiation
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
KR102117501B1 (ko) 2016-10-24 2020-06-01 스미또모 가가꾸 가부시키가이샤 세퍼레이터 및 세퍼레이터를 포함하는 이차 전지
IL266361B2 (en) 2016-11-14 2024-02-01 Novartis Ag Methods and preparations for the treatment of cartilage damage and arthritis
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
PE20210406A1 (es) 2018-07-25 2021-03-02 Novartis Ag Inhibidores de inflamasoma nlrp3
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN111973617A (zh) * 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
MX2022000094A (es) * 2019-07-04 2022-04-27 Cadila Healthcare Ltd Vacuna a base de angptl3 para el tratamiento de enfermedad hepática.
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
WO2022249040A1 (en) 2021-05-24 2022-12-01 Novartis Ag Methods for the treatment of osteoarthritis
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN118251594A (zh) 2021-11-10 2024-06-25 诺华股份有限公司 用于确定angptl多肽的生物活性的方法
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
KR20240087877A (ko) * 2022-12-09 2024-06-20 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
JP2003505350A (ja) 1999-07-20 2003-02-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030144498A1 (en) 2000-10-16 2003-07-31 Audrey Goddard TIE ligand homologues
ATE456655T1 (de) 2000-10-16 2010-02-15 Genentech Inc Behandlungsverfahren unter verwendung von wisp- polypeptiden
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
MXPA03009563A (es) 2001-04-19 2004-12-06 Scripps Research Inst Incorporacion in vivo de aminoacidos no naturales.
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1451578B1 (en) 2001-11-16 2013-08-21 Genentech, Inc. Use of angptl3 antagonists for the treatment of liver diseases
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
AU2003270454B2 (en) 2002-09-09 2010-05-20 Nektar Therapeutics Water-soluble polymer alkanals
ES2333422T3 (es) 2002-10-16 2010-02-22 The Scripps Research Institute Sintesis de glicoproteinas.
DE60327369D1 (de) 2002-10-16 2009-06-04 Scripps Research Inst Stellenspezifischer einbau von ketoaminosäuren in proteine
JP5642916B2 (ja) 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
BRPI0412272A (pt) 2003-07-07 2006-09-05 Scripps Research Inst composições de pares de lisil-trna e aminoacil-trna sintetase ortogonais e usos destes
AU2005286722B2 (en) 2004-09-21 2010-12-02 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
JP5135504B2 (ja) 2004-10-27 2013-02-06 ザ スクリプス リサーチ インスティチュート 非天然アミノ酸のインビボ組込み用直交翻訳成分
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
EP1899457B1 (en) 2005-05-24 2012-09-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
PT1991680E (pt) 2006-03-09 2013-10-30 Scripps Research Inst Sistema para a expressão de componentes ortogonais de tradução em células hospedeiras eubacterianas
CN103356694B (zh) 2006-12-06 2015-09-02 生化学工业株式会社 治疗关节炎病症的长效药剂
PL2121751T3 (pl) 2006-12-08 2017-07-31 Lexicon Pharmaceuticals, Inc. Przeciwciała monoklonalne przeciwko ANGPTL3
WO2008098930A1 (en) 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
SG177318A1 (en) * 2009-07-14 2012-03-29 Scripps Research Inst Mesenchymal stem cell differentiation
CA2826142A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
ES2651113T3 (es) 2012-06-25 2018-01-24 The Brigham And Women's Hospital, Inc. Tratamientos terapéuticos dirigidos
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
JP6918871B2 (ja) 2021-08-11
UY35368A (es) 2014-10-31
CU20150097A7 (es) 2016-05-30
AU2016277608A1 (en) 2017-01-12
AU2016203028A1 (en) 2016-05-26
CL2015002443A1 (es) 2016-05-20
SG11201506490TA (en) 2015-09-29
AU2016203028C1 (en) 2017-06-01
BR112015021269B1 (pt) 2023-04-11
CR20200290A (es) 2020-08-27
JP2021178841A (ja) 2021-11-18
CN111808182A (zh) 2020-10-23
KR20150125712A (ko) 2015-11-09
MX365157B (es) 2019-05-24
PH12015501983A1 (en) 2016-01-11
PL2964250T3 (pl) 2018-10-31
CY1120729T1 (el) 2019-12-11
EP2964250B1 (en) 2018-05-16
US9649359B2 (en) 2017-05-16
PT2964250T (pt) 2018-10-19
US20170252407A1 (en) 2017-09-07
AU2016277608B2 (en) 2018-04-05
AU2016203028B2 (en) 2017-02-02
TN2015000385A1 (en) 2017-01-03
ZA201505966B (en) 2017-03-29
LT2964250T (lt) 2018-07-25
HRP20181269T1 (hr) 2018-10-19
US20200268849A1 (en) 2020-08-27
CO7461145A2 (es) 2015-11-30
DK2964250T3 (da) 2018-08-06
US10328126B2 (en) 2019-06-25
US20220184182A1 (en) 2022-06-16
EP3391900A1 (en) 2018-10-24
JP2016510763A (ja) 2016-04-11
EA035158B1 (ru) 2020-05-06
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
CN105025917B (zh) 2020-08-18
WO2014138687A1 (en) 2014-09-12
CU24301B1 (es) 2017-12-08
CA2903448A1 (en) 2014-09-12
KR102267341B1 (ko) 2021-06-21
ECSP15042898A (es) 2019-03-29
JP6567429B2 (ja) 2019-08-28
BR122016021558A2 (pt) 2019-07-30
PH12015501983B1 (en) 2016-01-11
AU2014225348B2 (en) 2016-03-31
MY173172A (en) 2020-01-02
TW201444865A (zh) 2014-12-01
US11179442B2 (en) 2021-11-23
US20160008433A1 (en) 2016-01-14
BR112015021269A2 (pt) 2017-10-10
CA2903448C (en) 2021-03-23
EP2964250A1 (en) 2016-01-13
JP2020015725A (ja) 2020-01-30
AP2015008675A0 (en) 2015-08-31
HUE038499T2 (hu) 2018-10-29
BR122016021558B1 (pt) 2023-03-28
AU2014225348A1 (en) 2015-09-10
CN105025917A (zh) 2015-11-04
IL240727A0 (en) 2015-10-29
JO3564B1 (ar) 2020-07-05
IL240727B (en) 2019-12-31
MX2015011963A (es) 2015-12-09
NZ711037A (en) 2018-07-27
TWI634124B (zh) 2018-09-01
ES2684349T3 (es) 2018-10-02
EA201591661A1 (ru) 2015-12-30
HK1214754A1 (zh) 2016-08-05
RS57446B1 (sr) 2018-09-28

Similar Documents

Publication Publication Date Title
CR20150466A (es) Péptidos y composiciones para el tratamiento de daño articular
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
BR112017010177A2 (pt) composição para tratamento de tecido
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CO2017001387A2 (es) Proceso para purificación de rhu-gcsf
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
BR112017013579A2 (pt) método para uso de uma cepa de bacillus subtilis ou bacillus pumilus para tratar ou impedir a doença do abacaxi.